Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
A sign sits in front of Shire's manufacturing facility in Lexington, Mass., July 18, 2014. (© Brian Snyder / Reuters)
A sign sits in front of Shire's manufacturing facility in Lexington, Mass., July 18, 2014. (© Brian Snyder / Reuters)

Shire in advanced talks to acquire U.S. drug maker Baxalta, sources say Add to ...

Shire PLC is in advanced talks to acquire Baxalta Inc. for about $32-billion (U.S.) in cash and stock, excluding debt, according to people familiar with the matter.

The two drug makers may announce a deal as soon as this week, the people said, asking not to be identified as the matter isn’t public. The price being discussed is $46.50 to $48 a share, two of the people said. Final details of the transaction are still being negotiated and the timing and structure of any offer may change, they said.

Representatives for Baxalta didn’t immediately respond to requests for comment outside of regular business hours. A spokeswoman for Shire declined to comment.

In July, Baxalta rebuffed an unsolicited $30-billion all-stock bid from Shire that valued the company at $45.23 a share.

The Deerfield, Ill.-based company has been seeking a higher offer that includes cash, people familiar with the matter said last month.

Shire structured the original bid as an all-stock transaction to help preserve tax benefits of Baxalta’s July spinoff from Baxter International Inc. Baxalta could benefit from a lower tax rate if taken over by Shire, which has a Dublin legal address despite having many operations elsewhere. The combination would yield an effective tax rate of 16 per cent to 17 per cent, Shire has said. Baxalta had projected a tax rate of 23 per cent in 2016.

If a deal succeeds, the enlarged company would generate $20-billion in sales by 2020, with as many as 30 new drugs to launch over five years for diseases ranging from dry eye disease to hemophilia, Shire has said.

Shire has been focusing on acquiring companies with treatments for rare conditions, including the November purchase of Dyax Corp. for $5.9-billion and the $5-billion acquisition of NPS Pharmaceuticals Inc. in February.

The drug maker has been bulking up following AbbVie Inc.’s abandoned $52-billion buyout of the company last year.

Report Typo/Error

In the know

The Globe Recommends

loading

Most popular videos »

Highlights

More from The Globe and Mail

Most popular